Climb Bio Inc (CLYM) Key Metrics
CLYM valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $564.0M
- Enterprise value
- $537.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.0 10-yr median 0.8
- EV / EBITDA
- 0.6
- Dividend yield
- —
- Beta
- −0.03
CLYM key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCLYM valuation Price multiples at each fiscal year-end price.
CLYM returns How much profit the business earns on the capital it uses.
CLYM per-share figures Results divided by the shares outstanding at year-end.
CLYM financial health Debt, liquidity and how easily interest is covered.
CLYM valuation history
CLYM returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CLYM debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CLYM price vs earnings per share
CLYM key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $271.2M | $86.7M | $72.9M | $96.6M | $128.2M | — | — |
| Enterprise value | $170.7M | −$63.7M | −$33.6M | −$26.5M | −$8.2M | — | — |
| Price / book | 1.7 | 0.4 | 0.7 | 0.8 | 0.8 | — | — |
| Earnings yield | −22.1% | −85.2% | −48.2% | −46.9% | −37.0% | — | — |
| Free cash flow yield | −20.1% | −18.0% | −28.3% | −38.7% | −28.1% | — | — |
| Share price at fiscal year-end | $4.00 | $1.80 | $2.70 | $3.67 | $10.46 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.88 | −$1.53 | −$1.30 | −$1.72 | −$3.87 | −$1.77 | −$0.56 |
| Operating cash flow per share | −$0.80 | −$0.32 | −$0.76 | −$1.42 | −$2.94 | −$1.21 | −$0.43 |
| Free cash flow per share | −$0.80 | −$0.32 | −$0.76 | −$1.42 | −$2.94 | −$1.21 | −$0.43 |
| Cash per share | $1.49 | $3.13 | $3.96 | $4.70 | $11.13 | $1.76 | $1.82 |
| Book value per share | $2.37 | $4.40 | $3.99 | $4.89 | $13.64 | $1.85 | $1.77 |
| Tangible book value per share | $2.37 | $4.40 | $3.99 | $4.89 | $13.64 | $1.85 | $1.77 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.01 | $0.01 | $0.01 | $0.02 | — | — | — |
| Shares outstanding | 67.8M | 48.2M | 27.0M | 26.3M | 12.3M | 11.7M | 11.7M |
| Change in shares outstanding | +40.8% | +78.5% | +2.6% | +114.6% | +5.1% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −32.1% | −46.3% | −29.7% | −30.6% | −50.3% | −98.0% | −31.8% |
| Return on invested capital (ROIC) | −88.3% | −206.9% | −938.7% | −196.2% | −177.2% | — | — |
| Return on assets (ROA) | −31.1% | −45.1% | −28.6% | −29.4% | −48.0% | −89.8% | −30.6% |
| Return on tangible assets | −35.7% | −34.0% | −31.8% | −33.5% | −27.4% | −83.9% | −30.6% |
| Financial health | |||||||
| Total debt | $541,000 | $532,000 | $349,000 | $480,000 | — | — | — |
| Cash & short-term investments | $101.1M | $150.9M | $106.8M | $123.6M | $136.5M | $20.5M | $21.2M |
| Net debt | −$100.5M | −$150.4M | −$106.4M | −$123.1M | −$136.5M | −$20.5M | −$21.2M |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Debt / assets | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Current ratio | 15.16 | 31.41 | 38.92 | 22.04 | 24.58 | 7.18 | 27.18 |
| Quick ratio | 15.16 | 31.41 | 38.92 | 22.04 | 24.58 | 7.18 | 27.18 |
| Working capital | $98.9M | $149.9M | $107.4M | $128.3M | $142.2M | $18.9M | $20.5M |
| Invested capital | $59.9M | $61.5M | $1.1M | $5.6M | $30.7M | $1.1M | −$611,000 |
| Tangible asset value | $160.5M | $211.9M | $107.6M | $128.7M | $167.2M | $21.6M | $20.6M |
| Net current asset value | $98.6M | $149.6M | $107.4M | $128.1M | $142.2M | $18.9M | $20.5M |
| Graham net-net per share | $1.38 | $3.04 | $3.92 | $4.64 | $11.04 | $1.49 | $1.75 |
| Capital allocation | |||||||
| Capex / depreciation | 1.92 | — | — | — | — | — | — |
| Efficiency | |||||||
| Days payables outstanding | 5,595.4 | — | — | — | — | — | — |
| Receivables turnover | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Payables turnover | 0.07 | — | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | $1.8M | $4.5M | $6.5M | $6.5M | — | — |
| Average payables | $1.5M | $385,500 | $408,000 | $1.1M | $1.2M | $866,500 | $647,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CLYM's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CLYM valuation and financial ratios
Climb Bio earned a return on equity of −32.1% and a return on invested capital of −88.3% in fiscal 2025. It ended the year with $0.5 million of debt and $101.1 million in cash and short-term investments, a net cash position of $100.5 million. The share count rose 481.5% from 11.7M to 67.8M over 6 years.
See the CLYM income statement, the CLYM chart for price history, or the CLYM stock overview for the latest quote and news.
CLYM key metrics FAQ
What is Climb Bio's return on equity?
Climb Bio's return on equity (ROE) was −32.1% in fiscal 2025: net income of -$59.9 million on average shareholders' equity of $186.2 million.
What is Climb Bio's ROIC?
Climb Bio's return on invested capital was −88.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Climb Bio have?
Climb Bio had total debt of $0.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Climb Bio's free cash flow yield?
Climb Bio generated -$54.5 million of free cash flow in fiscal 2025, a free cash flow yield of −20.1% on its market value at year-end ($271.2 million).
What is Climb Bio's current ratio?
Climb Bio's current ratio was 15.16 at the end of fiscal 2025: current assets were 15.16 times current liabilities.